HIV cascade of care: integrating lessons learned from COVID-19 pandemic

Dr. Jean-Pierre Routy | December 1, 2021 12-1pm ET

Learning objectives: (1) Compared cascades of care endpoints before the COVID-19 pandemic to those of today. (2) Understood the weaknesses of the cascade of HIV care. (3) Reviewed potential upgrade of the cascade of HIV care. (4) Appreciated conditions that would insulate the cascade of HIV care against potential future challenges.

ABOUT THE SPEAKER: Dr. Jean-Pierre Routy, MD FRCPC

Clinical Director of the Chronic Viral Illness Service, Louis Lowenstein Chair in Hematology & Oncology
Local Co-Chair 24th International AIDS Conference – July 29 – August 2, 2022 Montreal

Dr. Jean-Pierre Routy is a Professor of Medicine, Clinical Director of the Chronic Viral Illness Service, Louis Lowenstein Chair in Hematology & Oncology. Dr. Routy has dedicated the last two decades bringing science and treatment innovation to help combat the health challenges of AIDS and cancer care. His fight against AIDS-related malignancies has led him to obtain in 2012 the McGill University Louis Lowenstein Chair in Hematology & Oncology. As an FRSQ Clinician-Scientist, he was able to implement the Montreal Primary HIV-Infection cohort, which generated important findings in HIV pathogenesis and drug resistance. His achievements have led Dr. Routy to become the National Co-Director of the Immunotherapy and Vaccine Core at the Canadian Health Research Institutes for HIV Trials Network. Since 2011, he co-chairs the Eradication Clinical Working Group for the International AIDS Society.


ABOUT THE MODERATOR: Dr. Marc Steben

Family physician, president of IUSTI Canada and president elect International Society for STD Research

As a family physician, Marc concentrates his clinical interest on sexual health,mainly chronic genital diseases. Research,development and publications field include therapeutic approaches to chronic genital pain, prevention and treatment of genital herpes and development of HPV prophylactic vaccine.

Previous
Previous

Disseminated Gonococcal Infection: The Return of a Rare STI

Next
Next

A new model for gonorrhea control in Canada: Surveillance, a new way of selecting best therapeutics and maybe a vaccine?